Results 101 to 110 of about 610,146 (137)

Serum complement system activation in normal healing and atrophic non-union of human long bone fractures. [PDF]

Front Immunol
El-Sherbiny YM, Ali YM, Jones E, Giannoudis PV, El-Jawhari JJ.   +4 more
europepmc   +1 more source

Role of CD4+ T cell mannose binding lectin in Schistosoma-induced pulmonary hypertension. [PDF]

JCI Insight
Mickael C, Fonseca Balladares DC, Kumar R, Lee MH, Nolan K, Sanders L, Tuscan KJ, Prasad R, Londono P, Oliveira FP, Pyper KB, Molofsky AB, Tuder RM, Stenmark KR, Graham BB.   +14 more
europepmc   +1 more source

Overexpression of key complement regulators in glioblastoma. [PDF]

PLoS One
Blomberg L, Raba L, Bengzon J, Osther K, Nittby Redebrandt H.   +4 more
europepmc   +1 more source

New Anticomplement Drugs in Nephrology: Mechanism and Indication.

Kidney Blood Press Res
Macciò L, Russo E, Costigliolo F, Battaglia Y, Viazzi F, Esposito P.   +5 more
europepmc   +1 more source

Complement Inhibition in Geographic Atrophy: Clinical Evidence for Pegcetacoplan and Avacincaptad Pegol. [PDF]

Cureus
Orozco Loaiza G, Alfaro Guerra MJ, Murillo Sotela A, Villalobos Villalobos P.   +3 more
europepmc   +1 more source

Structural insights into C3 convertase activity of the classical pathway of complement. [PDF]

Nat Commun
De la O Becerra KI, Brondijk THC, Serna Martin I, Gros P.   +3 more
europepmc   +1 more source

Complement as a driver of immune-vascular heterogeneity across preeclampsia subtypes: toward a precision medicine framework. [PDF]

Front Immunol
Ge Y, Gao T.
europepmc   +1 more source

CRP (C-Reactive Protein) Revisited: An Old Yet New Biomarker of Acute and Chronic Inflammation. [PDF]

Cells
Nagasawa M.
europepmc   +1 more source

Complement and kidney diseases: unlocking the opportunity of targeted treatments for glomerular diseases, including IgA nephropathy. [PDF]

Pediatr Nephrol
Wade J, Thomas DC, Pickering MC, Medjeral-Thomas NR.   +3 more
europepmc   +1 more source

The C-terminal domain of Staphylococcus aureus Efb recruits FHR-2 to C3b, synergistically inhibiting the terminal complement pathway. [PDF]

J Immunol
Duan H, Kortvely E, Mary JL, Hauck SM, Geisbrecht BV.   +4 more
europepmc   +1 more source